# TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)

> **NCT02043847** · PHASE1 · COMPLETED · sponsor: **University of Illinois at Chicago** · enrollment: 12 (actual)

## Conditions studied

- Multiple Myeloma, Relapsed
- Multiple Myeloma, Refractory to Standard Treatment

## Interventions

- **RADIATION:** Total Marrow Irradiation
- **DRUG:** Melphalan
- **DRUG:** Filgrastim (G-CSF)
- **PROCEDURE:** Autologous transplant
- **RADIATION:** Total Marrow Irradiation
- **DRUG:** Melphalan
- **DRUG:** Filgrastim (G-CSF)
- **PROCEDURE:** Autologous transplant
- **RADIATION:** Total Marrow Irradiation
- **DRUG:** Melphalan
- **DRUG:** Filgrastim (G-CSF)
- **PROCEDURE:** Autologous transplant

## Key facts

- **NCT ID:** NCT02043847
- **Lead sponsor:** University of Illinois at Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-14
- **Primary completion:** 2016-09-14
- **Final completion:** 2016-09-14
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02043847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02043847, "TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02043847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*